Compare NBTX & RPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBTX | RPC |
|---|---|---|
| Founded | 2003 | 1992 |
| Country | France | United States |
| Employees | N/A | 326 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 911.9M |
| IPO Year | 2018 | N/A |
| Metric | NBTX | RPC |
|---|---|---|
| Price | $33.98 | $8.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $36.00 | $11.00 |
| AVG Volume (30 Days) | 52.0K | ★ 325.6K |
| Earning Date | 03-31-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.96% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $58.17 | $16.82 |
| Revenue Next Year | N/A | $15.80 |
| P/E Ratio | ★ N/A | $53.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.29 | $6.79 |
| 52 Week High | $57.14 | $9.32 |
| Indicator | NBTX | RPC |
|---|---|---|
| Relative Strength Index (RSI) | 39.26 | 53.85 |
| Support Level | $29.64 | $8.02 |
| Resistance Level | $34.66 | $8.76 |
| Average True Range (ATR) | 2.41 | 0.27 |
| MACD | -1.27 | -0.04 |
| Stochastic Oscillator | 16.43 | 65.73 |
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
Ridgepost Capital Inc, formelrly P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Its Revenue mainly comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.